Ask AI

Advancing Frontline Strategies in BRAF-Mutant mCRC

This program will explore the expanding role of biomarker-driven therapy in the frontline setting, with particular emphasis on targeted treatment approaches for patients with BRAF V600E–mutant disease. In addition to pivotal trial results, the program will address practical considerations including early and comprehensive molecular testing, interpretation of biomarker results at diagnosis, integration of targeted therapy into first-line treatment planning, and implications for subsequent sequencing.

Program Content

Activities

Advancing Frontline Strategies in BRAF-Mutant mCRC
Advancing Frontline Strategies in BRAF-Mutant mCRC
Video
Congratulations: You achieved a completion on 04/09/2022

Released: April 22, 2026